Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.5%

396 terminated/withdrawn out of 2140 trials

Success Rate

75.3%

-11.2% vs industry average

Late-Stage Pipeline

155 trials in Phase 3/4

Results Transparency

54%

648 of 1208 completed trials have results

Key Signals

267 recruiting648 with results276 terminated120 withdrawn

Enrollment Performance

Analytics

N/A

872(49.6%)

Phase 2

331(18.8%)

Phase 1

327(18.6%)

Phase 4

85(4.8%)

Early Phase 1

72(4.1%)

Phase 3

70(4.0%)

1757Total

N/A(872)

Phase 2(331)

Phase 1(327)

Phase 4(85)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2140)

Showing 20 of 2140 trials

NCT05124132Not ApplicableEnrolling By Invitation

Resilience and Brain Health of Older Adults (MEDEX-2)

Role: lead

NCT06397989Not ApplicableActive Not Recruiting

Peanut-based School Meals in Rural Ghana to Improve Attendance and Retention

Role: lead

NCT04785352Not ApplicableCompleted

Grandi Byen: Test of an Integrated Parenting and Nutrition Intervention

Role: lead

NCT07294144Phase 2Recruiting

Tofersen in Non-SOD1 ALS

Role: lead

NCT06981208Not ApplicableRecruiting

ChatGPT & Surgeon Synergy: Redefining Breast Reconstruction Consultations for Enhanced Patient Engagement and Satisfaction

Role: lead

NCT07200089Phase 1Recruiting

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

Role: lead

NCT07313592Recruiting

Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients

Role: lead

NCT05618080Active Not Recruiting

LGMD R1 Natural History Study

Role: collaborator

NCT05521984Phase 1Recruiting

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Role: lead

NCT06439992Recruiting

Beta Amyloid PET Imaging for Alzheimer Disease With [18F]-Fluselenamyl

Role: lead

NCT05651620Active Not Recruiting

The CALERIE™ Legacy Study

Role: collaborator

NCT05731440Active Not Recruiting

Fluselenamyl - Beta Amyloid PET Imaging for Alzheimer Disease

Role: lead

NCT06129838Recruiting

Investigation of Inflammation in Alzheimer's Disease and Related Dementias (ADRD) Using [11C]-CS1P1

Role: lead

NCT06367465Recruiting

Feasibility and Acceptability of HCV Treatment in Pregnancy

Role: lead

NCT02414178Enrolling By Invitation

F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)

Role: lead

NCT07039760Early Phase 1Not Yet Recruiting

Asciminib With or Without Sildenafil for Brain Tumors

Role: lead

NCT07635524Phase 2Not Yet Recruiting

A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.

Role: collaborator

NCT05446805Recruiting

Depression and Driving

Role: lead

NCT06310655Not ApplicableCompleted

Online Proton Adaptive Radiotherapy

Role: lead

NCT07200102Phase 1Recruiting

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

Role: lead